UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy

Alimentary pharmacology & therapeutics, 2018-04, Vol.47 (7), p.1001-1011

2018

Volltextzugriff (PDF)

The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States

Journal of hepatology, 2017, Vol.66 (1), p.S713-S714

2017

Volltextzugriff (PDF)

892 ANEMIA PREDICTS SUSTAINED VIROLOGIC RESPONSE IN CIRRHOTIC AND NON-CIRRHOTIC CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN FOUR CLINICAL TRIALS

Journal of hepatology, 2013-04, Vol.58, p.S367-S367

2013

Volltextzugriff (PDF)

Use of ledipasvir/sofosbuvir in patients with advanced chronic kidney disease (eGFR ≤ 30 mL/min): a case series

Journal of hepatology, 2017, Vol.66 (1), p.S721-S722

2017

Volltextzugriff (PDF)

Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1–6: results of the HCV-TARGET Study

Journal of hepatology, 2017, Vol.66 (1), p.S716-S717

2017

Volltextzugriff (PDF)

MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection

Journal of hepatology, 2017, Vol.66 (1), p.S90-S91

2017

Volltextzugriff (PDF)

P466 SCREENING FOR ZINC DEFICIENCY IS NECESSARY IN THE MANAGEMENT OF PATIENTS WITH CIRRHOSIS

Journal of hepatology, 2014-04, Vol.60 (1), p.S224-S224

2014

Volltextzugriff (PDF)

Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies

Journal of hepatology, 2016, Vol.64 (2), p.S399-S400

2016

Volltextzugriff (PDF)

P0889 : Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV) in non-cirrhotic patients with HCV genotype 1 infection

Journal of hepatology, 2015-04, Vol.62, p.S676-S677

2015

Volltextzugriff (PDF)

P0781 : High SVR rates despite multiple negative predictors in genotype 1 patients receiving ombitasvir/paritaprevir/R, dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials

Journal of hepatology, 2015-04, Vol.62, p.S623-S624

2015

Volltextzugriff (PDF)

Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis

Journal of hepatology, 2016, Vol.64 (2), p.S758-S759

2016

Volltextzugriff (PDF)

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals

Journal of hepatology, 2016, Vol.64 (2), p.S139-S140

2016

Volltextzugriff (PDF)

815 FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON alfa/RIBAVIRIN IN TREATMENT-NAÏVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHESYS COHORTS

Journal of hepatology, 2013-04, Vol.58, p.S334-S334

2013

Volltextzugriff (PDF)

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

The New England journal of medicine, 2015-12, Vol.373 (27), p.2608-2617

2015

Volltextzugriff (PDF)

Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin

Journal of viral hepatitis, 2012-02, Vol.19 (2), p.94-102

2012

Volltextzugriff (PDF)

170 DIASTOLIC DYSFUNCTION PREDICTS MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) CREATION

Journal of hepatology, 2011-03, Vol.54, p.S73-S73

2011

Volltextzugriff (PDF)

1158 SUBTYPE 1B DOES NOT CONFER A TREATMENT ADVANTAGE TO HCV INFECTED AFRICAN AMERICAN PATIENTS TREATED WITH PEG+RBV

Journal of hepatology, 2011-03, Vol.54, p.S457-S458

2011

Volltextzugriff (PDF)

619 IDENTIFYING PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO MAY BENEFIT FROM EXTENDED PEGINTERFERON ALFA-2A/RIBAVIRIN THERAPY BEYOND 48 WEEKS

Journal of hepatology, 2009, Vol.50, p.S227-S228

2009

Volltextzugriff (PDF)

P64 Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir

Journal of Virus Eradication, 2017-08, Vol.3, p.34

2017

Volltextzugriff (PDF)

RWD48 Economic Burden Associated With Sobriety Restrictions to Direct-Acting Antiviral Access Among Medicaid Patients With Hepatitis C Virus: A Retrospective Analysis of Claims from States With and Without Restrictions

Value in health, 2024-06, Vol.27 (6), p.S366-S366

2024

Volltextzugriff (PDF)

147 EXCESSIVE REDUCTION IN HVPG IS PREDICTIVE OF MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)

Journal of hepatology, 2011-03, Vol.54, p.S64-S64

2011

Volltextzugriff (PDF)

Alcoholic liver disease

Hepatology (Baltimore, Md.), 2010-01, Vol.51 (1), p.307-328

2010

Volltextzugriff (PDF)

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Gastroenterology (New York, N.Y. 1943), 2016-02, Vol.150 (2), p.419-429

2016

Volltextzugriff (PDF)

Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study

Journal of hepatology, 2019-09, Vol.71 (3), p.486-497

2019

Volltextzugriff (PDF)

SAT-216 - The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States

Journal of hepatology, 2017, Vol.66 (1), p.S713-S714

2017

Volltextzugriff (PDF)

1 – 25 von 609

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(430)
Mit Volltextzugriff
(570)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Sciences Exactes Et Technologie
(28)
Life Sciences & Biomedicine
(23)
Physique
(23)
Physics
(22)
Gastroenterology And Hepatology
(21)
Life Sciences
(21)
Physical Sciences
(21)
Etat Condense: Structure, Proprietes Mecaniques Et Thermiques
(17)
Humans
(17)
History
(16)
Exact Sciences And Technology
(13)
Gastroenterology & Hepatology
(12)
Humanities And Social Sciences
(11)
Chemistry
(9)
Female
(9)
Middle Aged
(9)
Physics, Condensed Matter
(9)
Sciences Biologiques Et Medicales
(9)
Sociologie
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy

The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States

892 ANEMIA PREDICTS SUSTAINED VIROLOGIC RESPONSE IN CIRRHOTIC AND NON-CIRRHOTIC CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN FOUR CLINICAL TRIALS

Use of ledipasvir/sofosbuvir in patients with advanced chronic kidney disease (eGFR ≤ 30 mL/min): a case series

Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1–6: results of the HCV-TARGET Study

MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection

P466 SCREENING FOR ZINC DEFICIENCY IS NECESSARY IN THE MANAGEMENT OF PATIENTS WITH CIRRHOSIS

Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies

P0889 : Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV) in non-cirrhotic patients with HCV genotype 1 infection

P0781 : High SVR rates despite multiple negative predictors in genotype 1 patients receiving ombitasvir/paritaprevir/R, dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials

Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals

815 FACTORS ASSOCIATED WITH INTOLERANCE TO PEGINTERFERON alfa/RIBAVIRIN IN TREATMENT-NAÏVE, CIRRHOTIC/NON-CIRRHOTIC HCV GENOTYPE 1-INFECTED PATIENTS: ANALYSIS OF DATA FROM THE MULTINATIONAL PROPHESYS COHORTS

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin

170 DIASTOLIC DYSFUNCTION PREDICTS MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) CREATION

1158 SUBTYPE 1B DOES NOT CONFER A TREATMENT ADVANTAGE TO HCV INFECTED AFRICAN AMERICAN PATIENTS TREATED WITH PEG+RBV

619 IDENTIFYING PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO MAY BENEFIT FROM EXTENDED PEGINTERFERON ALFA-2A/RIBAVIRIN THERAPY BEYOND 48 WEEKS

P64 Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir

RWD48 Economic Burden Associated With Sobriety Restrictions to Direct-Acting Antiviral Access Among Medicaid Patients With Hepatitis C Virus: A Retrospective Analysis of Claims from States With and Without Restrictions

147 EXCESSIVE REDUCTION IN HVPG IS PREDICTIVE OF MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)

Alcoholic liver disease

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study

SAT-216 - The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States

Suchergebnisse filtern